Julian Gangolli

Director at Outlook Therapeutics

Capital raised by Outlook Therapeutics

—

2 Form D filings · first filed Jan 2025 · Iselin, NJ

CURRENT ROLE: Director
SECTOR: Biotech
COMPANY FILINGS: 2
TEAM ON FILE: 2
FOUNDED: —
30D INTEREST: 5 ↗

Career

1 company on file

Outlook TherapeuticsBiotech · Iselin, NJsince Jan 2025

Director

Listed on Outlook Therapeutics's Form D filings

Company filings

via EDGAR · Form D for Outlook Therapeutics2

DateCompanyFormAmountRole on filing

Apr 23, 2026Outlook TherapeuticsForm D——

Form DApr 23, 2026 · Outlook Therapeutics—not a signer

Jan 17, 2025Outlook TherapeuticsForm D——

Form DJan 17, 2025 · Outlook Therapeutics—not a signer

Overview

Last filing Apr 23, 2026

Julian Gangolli is on file as Director at Outlook Therapeutics in Iselin, NJ. Outlook Therapeutics has 2 Form D filings on record.

Teammates

Outlook Therapeutics · 1

Lawrence KenyonInterim Chief Executive Officer, CFO, Treas & Sec'ySigner

Products

Outlook Therapeutics · 1

ONS-5010/LYTENAVA™ (bevacizumab-vikg)Retinal Disease Treatment

This product is an innovative ophthalmic formulation of bevacizumab specifically designed to meet FDA standards. It is intended for the treatment of various retinal diseases, particularly wet age-related macular degeneration.